Piramal Pharma Ltd completes USFDA inspection of Aurora facility with Zero Form-483 observations

The US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma Limited's facility at Aurora, Canada from 26th May 2025 to 30th May, 2025.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

The Company remains committed to maintain the highest standards of compliance.

Shares of Piramal Pharma Limited was last trading in BSE at Rs. 206.30 as compared to the previous close of Rs. 205.20. The total number of shares traded during the day was 283410 in over 3116 trades.

The stock hit an intraday high of Rs. 209.75 and intraday low of 205.35. The net turnover during the day was Rs. 58820228.00.

Source : Equity Bulls

Keywords

PiramalPharma PPLPHARMA INE0DK501011 Pharmaceuticals GMPInspection USFDA Aurora Canada ZeroForm483